Search

Author/Creator McColl, Damian J.

1. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. Issue 4 (4th July 2017)

Authors:
Pozniak, Anton; Flamm, Jason; Antinori, Andrea; Bloch, Mark; Ward, Douglas; Berenguer, Juan; Cote, Pierre; Andreatta, Kristen; Garner, William; Szwarcberg, Javier; Nguyen-Cleary, Thai; McColl, Damian J.; Piontkowsky, David
Journal:
HIV clinical trials
Issue:
Volume 18:Issue 4(2017)
Page Start:
141
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients. Issue 5 (September 2014)

Authors:
Kulkarni, Rima; Abram, Michael E.; McColl, Damian J.; Barnes, Tiffany; Fordyce, Marshall W.; Szwarcberg, Javier; Cheng, Andrew K.; Miller, Michael D.; White, Kirsten L.
Journal:
HIV clinical trials
Issue:
Volume 15:Issue 5(2014)
Page Start:
218
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search